A decision guide, not a sales page

This page is the long version. It covers what an exosome actually is, the mechanism that is proposed for it, the position UK regulation takes, how good the evidence really is, what a realistic outcome looks like, what it costs in 2026 and who should not have it. Nothing here is a recommendation to have the treatment or to avoid it.

What an exosome is

An exosome is a type of extracellular vesicle. Cells of many kinds release these particles constantly. Each one is a small sphere enclosed by a lipid membrane, typically somewhere in the range of thirty to one hundred and fifty nanometres across, which is far too small to see with an ordinary light microscope. Inside are proteins, lipids and nucleic acids, including short strands of RNA. On the outside sit membrane proteins that determine which cells the vesicle can dock with.

The word matters less than the biology. Scientific literature increasingly prefers the broader term extracellular vesicle, because separating true exosomes from other small vesicles released by a cell requires careful characterisation that many commercial preparations do not publish. When a clinic says exosomes, what is usually meant is a preparation containing extracellular vesicles and a considerable quantity of other material harvested alongside them, including growth factors and proteins from the culture in which the source cells were grown.

Source matters too. Vesicles used in aesthetic preparations have been derived from cultured human cells, from animal cells, and from plant material. These are not equivalent to one another biologically and they are not equivalent to one another in regulatory terms either. A preparation described only as exosomes tells you almost nothing. The specific questions to ask are set out on the consultation checklist.

The proposed mechanism

The rationale runs like this. Wound healing and tissue repair are coordinated by cells signalling to one another. Extracellular vesicles are one of the vehicles for that signalling, carrying molecular cargo from a donor cell to a recipient cell and altering what the recipient does. If you could deliver a concentrated dose of vesicles derived from a cell type associated with repair, the argument goes, you might push the recipient tissue towards a more regenerative pattern of behaviour: more collagen production in the dermis, less inflammation after an injury, a longer growth phase in a hair follicle.

That is a reasonable hypothesis. It is not a demonstrated fact in human skin or human scalp at the doses and by the routes used in aesthetic clinics. Between the hypothesis and the treatment sit several steps that have not been closed:

• Delivery. Intact skin is a barrier designed to keep particles of this size out. Applying a vesicle preparation to unbroken skin is very unlikely to deliver meaningful quantities into the dermis. That is precisely why the topical route is paired with microneedling, which breaches the barrier.
• Survival. A vesicle has to remain intact through storage, handling, reconstitution and application, and then survive in the tissue long enough to reach a target cell. Preparations differ enormously in how they are stabilised and stored, and few publish stability data.
• Dose. There is no agreed unit of dose. Particle counts, protein content and volume are all used, they are not interchangeable, and two products described in the same language may differ by orders of magnitude.
• Effect. Even if vesicles arrive intact in sufficient number, the clinical effect in a living human being over months has to be measured, not assumed. That is the step where the evidence is thinnest.

The UK regulatory reality

This is the section to read twice, because it is the one that clinic marketing most often leaves out.

No exosome product is licensed in the United Kingdom as an injectable medicine for aesthetic or hair indications. There is no marketing authorisation, granted by the Medicines and Healthcare products Regulatory Agency, permitting an exosome preparation to be injected into skin or scalp for cosmetic purposes. A treatment being available and being licensed are different things, and in this case only the first is true.

The regulatory framework around this is not a single rule but several that overlap:

• Medicines regulation. A product presented as having properties for treating or preventing disease, or administered to restore or modify a physiological function, is capable of meeting the legal definition of a medicinal product. A medicinal product requires an authorisation before it can be placed on the UK market.
• Advanced therapy rules. Products based on human cells or tissue that have been substantially manipulated, or used for a purpose other than their original function in the donor, can fall within the advanced therapy medicinal product framework, which carries a demanding evidence and manufacturing burden.
• Human tissue rules. Material of human origin brings obligations around consent, traceability and the licensing of establishments that procure, store and process it.
• Cosmetic product rules. A cosmetic is a product applied to the external surfaces of the body for cleaning, perfuming, changing appearance, protecting or correcting body odours. A cosmetic must be safe under normal and reasonably foreseeable use. Applying a cosmetic to skin that has just been deliberately breached with needles is difficult to characterise as normal and reasonably foreseeable use of a cosmetic.

That last point is the crux of the topical route, and it deserves stating without softening. A preparation sold for topical use has been assessed, if it has been assessed at all, for application to intact skin. Applying it immediately after microneedling delivers it through a breached barrier into living tissue. Whether that constitutes cosmetic use, unlicensed medicinal use, or something the framework did not anticipate is a question practitioners are entitled to be asked. Ask it. A practitioner who can explain what their product is classed as, who supplies it, and what the regulatory basis for using it in that way is has thought about the question. One who cannot has not.

Two further points follow from the regulatory position, and both affect you directly rather than in the abstract:

1. Unlicensed does not mean tested and rejected

   It means the assessment that produces a licence has not been completed and published for this use. That is a statement about the absence of a body of evidence, not a finding of harm. It is also not reassurance. The whole point of licensing is that someone independent has examined the manufacturing, the quality control and the clinical data before a product reaches a patient.

2. Redress is weaker outside the licensed route

   If something goes wrong with a licensed medicine there is a defined reporting route, a regulator with a file on the product, and a manufacturer that can be held to the terms of its authorisation. Outside that route the position is less defined. You still have the professional regulator that governs the practitioner, and you should still report a suspected adverse reaction, but the product itself sits in a weaker framework.

Regulatory positions change. Nothing on this page should be taken as the last word on a moving subject, and the current position should be checked directly with the MHRA. What will not change is the principle: ask what the product is, ask what it is classed as, and treat an evasive answer as an answer.

What a session actually involves

Protocols vary between clinics, and no protocol is standardised in the way a licensed medicine's would be. The common shape of a session is as follows.

You are assessed and consented. Topical anaesthetic is applied to the area and left for twenty to forty minutes. The skin or scalp is cleansed. A microneedling device is passed over the area at a set depth, producing controlled micro injuries and a degree of pinpoint bleeding. The vesicle preparation is then applied to the surface, often massaged in, sometimes with a further light pass of the device. The area is left to settle. You leave with instructions to avoid make up, exercise, heat and sun for a period, usually twenty four to seventy two hours.

A face session including anaesthetic time takes around sixty to ninety minutes. A scalp session is similar. A course of three sessions spaced two to four weeks apart is the most commonly recommended starting protocol, with maintenance suggested afterwards at intervals that vary widely between clinics, which itself tells you that the interval is not evidence based.

How good the evidence is

Short version: early, uneven and mostly not the kind of evidence that would support a confident claim. The evidence page goes through this properly. The summary here is what you need before a consultation.

The published literature is dominated by laboratory work and animal studies. Human clinical work exists but is characterised by small numbers of participants, short follow up, single centres, absent or weak control groups, subjective outcome measures such as investigator satisfaction scales, and frequent involvement of the companies that supply the preparations. None of that makes the findings worthless. It does mean that a positive result in such a study is a reason to run a better study, not a reason to promise a patient an outcome.

The deeper problem is comparability. Two products both described as exosomes may come from different source cells, be purified by different methods, be characterised to different standards and be dosed differently. A study of one tells you very little about another. In a licensed medicine that variability is controlled by the authorisation. Here it is not controlled at all.

There is no reliable UK specific outcome data for exosome treatments in aesthetics or hair. No national registry collects it, no professional body publishes aggregate outcomes, and the treatment is not one that the National Institute for Health and Care Excellence has appraised for cosmetic use. Where a figure is quoted to you, ask where it came from.

Realistic outcomes

If you go ahead, the realistic expectation is a modest change, visible mainly to you, developing over months rather than weeks, and difficult to separate from the effect of the microneedling that delivered it. Skin quality measures such as smoothness and evenness are the most commonly reported area of change. For hair, any change in density takes at least three to six months to assess because of how slowly the hair cycle turns, and a course completed in six weeks cannot be judged at the end of it.

What the treatment cannot do is worth stating just as plainly. It does not lift tissue that has descended. It does not remove established scarring. It does not regrow hair from a follicle that has been lost rather than miniaturised. It is not a substitute for treatments with a licence and a proper evidence base where those exist, which for hair loss they do. See exosomes for hair loss for that comparison and the alternatives page for the wider picture.

What it costs in the UK in 2026

These are indicative ranges collected from how the treatment is commonly sold in the UK, not quotations, and not an average. London sits at or above the upper end of every band. The cost page breaks this down by area and by course, and covers what actually drives the number.

Two notes on price. First, a low price for this treatment usually reflects the preparation used rather than a generous clinic, and there is no way for you to verify what is in a vial. Second, a package paid for in advance transfers all the risk to you, because you have committed to sessions two and three before you have any information about whether session one did anything.

Who should not have it

This is not a complete list and it is not a substitute for an assessment. It is the set of situations in which a careful practitioner would decline or defer, and if any of them apply to you, say so at consultation.

• Pregnancy and breastfeeding. There is no safety data supporting use, and the absence of data is itself the reason to decline.
• Active infection, active inflammatory acne, or broken or inflamed skin in the treatment area.
• A history of keloid or hypertrophic scarring, because the delivery step is a deliberate skin injury.
• Bleeding disorders or anticoagulant therapy that has not been discussed with the prescribing clinician.
• Immunosuppression, active autoimmune disease, or current cancer treatment, without specialist input.
• Recent oral isotretinoin, where most practitioners defer needling procedures for a period.
• Known allergy to any component of the preparation, which is a question you can only ask if the components are disclosed.
• Undiagnosed hair loss. Sudden shedding, patchy loss or scalp inflammation needs a diagnosis first. See the British Association of Dermatologists patient information for the range of conditions involved.
• An expectation that this will produce a result only surgery could produce.

How to decide

A reasonable way through this is to separate three questions that usually get asked as one.

1. Is my concern one this treatment plausibly addresses

   Skin quality and post procedure recovery are the areas with the most coherent rationale. Established scarring, tissue laxity and advanced hair loss are not. If your concern is in the second group, the answer is a different treatment, not a different clinic.

2. Have I compared it with the options that have a licence

   For androgenetic alopecia in particular there are treatments with regulatory approval and decades of clinical data. Choosing an unlicensed option before trying a licensed one is a decision you are entitled to make, but it should be a decision rather than an oversight.

3. Can this practitioner answer the regulatory question

   What is the product, where does it come from, what is it classed as, and on what basis is it being used in this way. A practitioner who answers those four questions clearly has engaged with the issue. Take the twelve questions with you and write the answers down.

Questions people ask before booking

Are exosome treatments legal in the UK

The position is more specific than legal or illegal. No exosome product holds a UK marketing authorisation as an injectable medicine for aesthetic or hair use, so injecting one is not a licensed route. What is commonly offered is topical application to skin prepared by microneedling, using a product supplied as a cosmetic or as a research or laboratory item. Whether a given product and a given use fall inside or outside medicines regulation depends on what the product is and how it is presented, which is why you should ask. Check the current position with the MHRA and read our regulation page in full.

Can exosomes be injected in the UK

No exosome product is licensed for injection in the UK for aesthetic or hair indications. If a clinic offers to inject one, ask directly what the product is, what it is classed as, and on what basis it is being injected. The absence of a licence for that route is a material fact and it should be disclosed to you before you consent, not after.

Do exosomes work for hair loss

The published human evidence is early, small in scale and not comparable between products. There is no large independent randomised trial supporting a specific outcome for a specific preparation. For androgenetic alopecia there are treatments with regulatory approval and a far deeper evidence base, and most people should understand those before considering an unlicensed option. Our hair loss page sets out the comparison.

How is this different from microneedling on its own

In practice the exosome protocol contains a microneedling treatment. Microneedling has its own evidence and produces its own wound healing response, so any result you see after a combined session has two possible explanations. Separating them requires a study in which one group receives needling plus the preparation and another receives needling plus a placebo, and that comparison is largely missing from the published work. This is covered on the evidence page.

What does it cost in the UK

As indicative 2026 ranges: roughly £250 to £600 for a single face session, £700 to £1,500 for a course of three for the face, £300 to £700 for a single scalp session and £850 to £1,800 for a course of three for the scalp. London sits at or above the top of each band. These are ranges rather than quotations and the cost page explains what drives the figure.

Is it safe

The needling component carries the risks any needling procedure carries: infection, prolonged redness, pigment change in darker skin types, and rarely scarring. The preparation component carries risks that cannot be quantified from published data, because the products are not standardised and there is no systematic UK collection of adverse events for them. Saying the risk is unquantified is a more accurate statement than saying it is low. See risks and regulation.

If you want to speak to someone

We are not a clinic and we give no medical advice. If you would like to, we can pass your details to a registered UK practitioner who will contact you directly. Nothing is booked on your behalf and there is no obligation. Read the regulation page first.

Make an enquiry

How to use this site

Nothing here is a booking funnel dressed as an article. Every page answers one question, states where the evidence is thin, and links to the page that follows it. Only the enquiry page carries a form, and it states above the fields exactly what happens to your details.

We are not a clinic. We do not treat anyone, we employ no practitioners and we give no medical advice. We name no exosome product and endorse none, and we have no affiliation with any manufacturer, supplier or distributor. Our editorial policy sets out how the content is produced and what we refuse to do, and about this guide explains why it exists at all.

Published by Northbank Media. Last reviewed 2026-07-31. Information only. This site is not a clinic and gives no medical advice.